Long term outcome and prognostic indicators in Posner Schlossman syndrome
Clinical & Experimental Ophthalmology · 2023
DOI: 10.1111/ceo.14292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, 2023. Verfasst von Danica M Joseph und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Eye Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Iridocyclitis, Glaucoma, Open-Angle, Glaucoma, Uveitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Posner Schlossman syndrome is a well‐defined uveitis entity that is characterised by relapsing remitting unilateral anterior uveitis with markedly raised intraocular pressure. The aim of this study was to determine the risk factors for progression in patients with Posner Schlossman syndrome.
Methods
Ninety‐eight patients were enrolled in a retrospective case series. Progression was defined as a composite endpoint of any of development of permanent glaucoma (in patients with no evidence of glaucomatous loss on presentation), corneal failure, or chronic inflammation. Relapse was defined as a resolving episode of inflammation not meeting the criteria for progression.
Results
Seventy seven percent of patients relapsed on average each 2.2 years. Forty percent of patients progressed. On univariate analysis, increased age at enrolment, immunocompromise at enrolment, the presence of glaucomatous optic neuropathy at enrolment, the performance of an anterior chamber tap and a positive anterior chamber tap were all associated with increased risk of progression. On multivariate analysis, age at enrolment, immunocompromise at enrolment, the performance of an anterior chamber tap, and the presence of glaucomatous optic neuropathy at enrolment were independently associated with increased risk of disease progression.
Conclusions
Posner Schlossman syndrome is not a benign uveitis entity and risk of both relapse and progression are high. Older patients, immunocompromised patients, patients with glaucomatous optic neuropathy at enrolment and those with a positive anterior chamber tap are all at increased risk of progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sydney Eye Hospital, Sydney, New South Wales, Australia.
- Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
- Centre for Eye Research Australia, The University of Melbourne, Melbourne, Victoria, Australia.
- Ophthalmology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
- College of Medicine & Public Health, Flinders University, Adelaide, South Australia, Australia.
- Faculty of Medicine & Health, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Danica M Joseph, Priya D Samalia, Peter J McCluskey
Zitieren
APA
Joseph, D. M., Lim, L. L., Samalia, P. D., Wells, J. M., McCluskey, P. J., Paul, E., & Hall, A. J. (2023). Long term outcome and prognostic indicators in Posner Schlossman syndrome. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14292
Vancouver
Joseph DM, Lim LL, Samalia PD, Wells JM, McCluskey PJ, Paul E, et al. Long term outcome and prognostic indicators in Posner Schlossman syndrome. Clinical & Experimental Ophthalmology. 2023. doi:10.1111/ceo.14292
BibTeX
@article{Joseph2023,
author = {Joseph, Danica M and Lim, Lyndell L and Samalia, Priya D and Wells, Jane M and McCluskey, Peter J and Paul, Eldho and Hall, Anthony J},
title = {Long term outcome and prognostic indicators in Posner Schlossman syndrome},
journal = {Clinical & Experimental Ophthalmology},
year = {2023},
doi = {10.1111/ceo.14292}
}
EUVIMED